Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Exclusion Criteria

• •Clinically significant cardiovascular disease within 12 months of screening
• •Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued
• •Type 1 diabetes or uncontrolled type 2 diabetes
• •Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening
• •History of chronic musculoskeletal symptoms such as fibromyalgia
• •Uncontrolled hypothyroidism
• •Liver disease or dysfunction
• •Renal dysfunction or nephritic syndrome
• •Gastrointestinal conditions or procedures or surgeries
• •Hematologic or coagulation disorders or low hemoglobin levels
• •HIV or AIDS
• •History of malignancy
• •History of drug or alcohol abuse within 2 years
• •Use of experimental or investigational drugs within 30 days of screening
• •Use of ETC-1002 in a previous clinical study